DUBLIN, Calif., Oct. 17 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that multiple abstracts have been accepted for poster presentations at the AACR-NCI-EORTC International Conference from Oct. 22-26 at the Moscone Center in San Francisco.
The poster presentations will focus on data concerning many of SuperGen's current oncology programs including the lead clinical compound, MP470, and its ability to suppress the repair of double stranded DNA breaks following treatment with DNA-damaging agents.
In addition to the poster presentations listed below, data on SuperGen's hypomethylating agent, S110, will be presented by Dr. Peter A. Jones on Wednesday, Oct. 24 at 8:00 a.m. in Plenary Session 3: Epigenetic Targets.
SuperGen's schedule of presentations is as follows:
Date Time (PDT) Abstract # and Title Number/Session
Tuesday, 12:30 p.m.- # 1026 - MP470 #A173
Oct. 23 2:30 p.m. suppresses repair of
double-strand breaks Poster Session A
5:30 p.m.- following treatment
7:30 p.m. with DNA-damaging
Wednesday, 12:30 p.m.- # 1038 - The #B140
Oct. 24 2:30 p.m. decitabine-derived
demethylating Poster Session B
5:30 p.m.- dinucleotide, S110
7:30 p.m. shows improved
activity due to
Thursday, 12:30 p.m.- # 907 - Effect of #C200
Oct. 25 2:30 p.m. small molecule
inhibitors of JAK2 Poster Session C
5:30 p.m.- kinase on modulating
7:30 p.m. signaling cascades
Thursday, 12:30 p.m.- # 985 - A small #C208
Oct. 25 2:30 p.m. molecule inhibitor of
Pim-1 kinase with Poster Session C
5:30 p.m.- activity in both
7:30 p.m. hematological and
Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.
This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.
Timothy L. Enns Mary M. Vegh
SuperGen, Inc. SuperGen, Inc.
SVP, Corporate Communications Manager, Investor Relations
& Business Development Tel: (925) 560-2845
Tel: (925) 560-0100 E-mail: firstname.lastname@example.org
|SOURCE SuperGen Inc.|
Copyright©2007 PR Newswire.
All rights reserved